Literature DB >> 26348893

Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver.

Alina Schreder1, Georgios Leandros Moschovakis1, Stephan Halle1, Jerome Schlue2, Chun-Wei Lee1, Angela Schippers3, Sascha David4, Günter Bernhardt1, Arnold Ganser5, Oliver Pabst6, Reinhold Förster1, Christian Koenecke7.   

Abstract

Homing of allogeneic donor T cells to recipient tissue is imperative for the development of acute graft-versus-host disease (GVHD) after bone marrow transplantation (BMT). In this study we show that alteration of T cell homing due to integrin-β7 deficiency on T cells or its ligand MAdCAM-1 in BMT recipients contributes to the pathophysiology of experimental GVHD. In contrast, lack of CC chemokine receptor 9 on donor T cells alters tissue homing but does not impact GVHD survival. We further demonstrate that MAdCAM-1 is aberrantly expressed in hepatic murine GVHD as well as in patients with active liver GVHD. However, infiltration of donor T cells in gut but not liver was dependent of MAdCAM-1 expression, indicating, that homing and/or retention of donor T cells rests on divergent molecular pathways depending on the GVHD target tissue.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone marrow transplantation; GVHD; T cells

Mesh:

Substances:

Year:  2015        PMID: 26348893     DOI: 10.1016/j.bbmt.2015.08.038

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

1.  Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.

Authors:  Ran Reshef; Alex Ganetsky; Edward P Acosta; Robin Blauser; Lisa Crisalli; Jessica McGraw; Noelle V Frey; Elizabeth O Hexner; James A Hoxie; Alison W Loren; Selina M Luger; James Mangan; Edward A Stadtmauer; Rosemarie Mick; Robert H Vonderheide; David L Porter
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-10       Impact factor: 5.742

2.  Donor T cell DNMT3a regulates alloreactivity in mouse models of hematopoietic stem cell transplantation.

Authors:  Yiouli P Ktena; Michael A Koldobskiy; Michael I Barbato; Han-Hsuan Fu; Leo Luznik; Nicolas J Llosa; Azeb Haile; Orly R Klein; Chen Liu; Christopher J Gamper; Kenneth R Cooke
Journal:  J Clin Invest       Date:  2022-07-01       Impact factor: 19.456

Review 3.  Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.

Authors:  Qingxiao Song; Ubaydah Nasri; Ryotaro Nakamura; Paul J Martin; Defu Zeng
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

4.  Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib.

Authors:  Alfonso Rodríguez-Gil; Virginia Escamilla-Gómez; Melanie Nufer; Félix Andújar-Sánchez; Teresa Lopes-Ramos; José Antonio Bejarano-García; Estefanía García-Guerrero; Cristina Calderón-Cabrera; Teresa Caballero-Velázquez; Clara Beatriz García-Calderón; Paola Hernández-Díaz; Juan Luis Reguera-Ortega; Nancy Rodríguez-Torres; Nuria Martínez-Cibrián; José Ignacio Rodríguez-Barbosa; Javier Villadiego; José Antonio Pérez-Simón
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

Review 5.  Resolution of acute intestinal graft-versus-host disease.

Authors:  Sindhu Thiagarajan; Markus F Neurath; Kai Hildner
Journal:  Semin Immunopathol       Date:  2019-10-31       Impact factor: 9.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.